Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Re: Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

Hadaschik B, Ost P.

Eur Urol. 2019 May 23. pii: S0302-2838(19)30420-8. doi: 10.1016/j.eururo.2019.05.016. [Epub ahead of print] No abstract available.

PMID:
31130433
2.

Editorial: assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer, a prospective single arm clinical study: California shows the way!

Choyke P.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S296-S299. doi: 10.21037/tau.2019.06.11. No abstract available.

3.

68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.

Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):31-39. doi: 10.1007/s00259-018-4189-7. Epub 2018 Oct 22.

PMID:
30350010
4.

68Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer.

Akdemir EN, Tuncel M, Akyol F, Bilen CY, Baydar DE, Karabulut E, Ozen H, Caglar M.

World J Urol. 2019 May;37(5):813-821. doi: 10.1007/s00345-018-2460-y. Epub 2018 Aug 27.

PMID:
30151600
5.

The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study.

Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, Eade T, Nguyen QA, Thompson BD, Cusick T, McCarthy M, Tang C, Ho B, Stricker PD, Scott AM.

J Nucl Med. 2018 Jan;59(1):82-88. doi: 10.2967/jnumed.117.197160. Epub 2017 Jun 23.

6.

68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.

von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.

Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15.

7.

Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.

Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, Doherty A, Gschwend JE, Schwaiger M, Eiber M.

J Nucl Med. 2016 Nov;57(11):1713-1719. Epub 2016 Jun 3.

8.

PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer.

Derlin T, Schmuck S, Juhl C, Zörgiebel J, Schneefeld SM, Walte ACA, Hueper K, von Klot CA, Henkenberens C, Christiansen H, Thackeray JT, Ross TL, Bengel FM.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):913-922. doi: 10.1007/s00259-017-3924-9. Epub 2018 Jan 7.

PMID:
29308527
9.

Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.

Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, Vasanawala S, Gambhir SS, Iagaru A.

J Nucl Med. 2016 Apr;57(4):557-62. doi: 10.2967/jnumed.115.168393. Epub 2015 Dec 10.

10.

Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.

Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N.

Eur Urol. 2016 Dec;70(6):926-937. doi: 10.1016/j.eururo.2016.06.021. Epub 2016 Jun 28. Review.

PMID:
27363387
11.

Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.

Budäus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, Graefen M, Steuber T, Rosenbaum C.

Eur Urol. 2016 Mar;69(3):393-6. doi: 10.1016/j.eururo.2015.06.010. Epub 2015 Jun 25.

PMID:
26116958
12.

Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].

Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG.

BMC Cancer. 2019 Jan 7;19(1):18. doi: 10.1186/s12885-018-5200-1. Erratum in: BMC Cancer. 2019 Jan 21;19(1):97.

13.

PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer.

Giesel FL, Fiedler H, Stefanova M, Sterzing F, Rius M, Kopka K, Moltz JH, Afshar-Oromieh A, Choyke PL, Haberkorn U, Kratochwil C.

Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1794-800. doi: 10.1007/s00259-015-3106-6. Epub 2015 Jul 11.

14.

Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.

Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AJ, Wester HJ, Gschwend J, Schwaiger M, Maurer T.

Eur Urol. 2016 Nov;70(5):829-836. doi: 10.1016/j.eururo.2015.12.053. Epub 2016 Jan 18.

PMID:
26795686
15.

Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.

Pfister D, Porres D, Heidenreich A, Heidegger I, Knuechel R, Steib F, Behrendt FF, Verburg FA.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1410-7. doi: 10.1007/s00259-016-3366-9. Epub 2016 Mar 19.

PMID:
26993315
16.

68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy.

Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, Schiavina R, Lodi F, Morganti AG, Fanti S.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):11-19. doi: 10.1007/s00259-018-4066-4. Epub 2018 Jun 15.

PMID:
29905907
17.

68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.

Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.

J Nucl Med. 2018 Feb;59(2):230-237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9.

18.

Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence.

Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F.

J Nucl Med. 2018 May;59(5):789-794. doi: 10.2967/jnumed.117.203257. Epub 2017 Dec 14.

19.

Integrated 68Ga-HBED-CC-PSMA-PET/MRI in patients with suspected recurrent prostate cancer.

Lütje S, Cohnen J, Gomez B, Grüneisen J, Sawicki L, Rübben H, Bockisch A, Umutlu L, Pöppel TD, Wetter A.

Nuklearmedizin. 2017 Jun 13;56(3):73-81. doi: 10.3413/Nukmed-0850-16-09. Epub 2017 Apr 12.

PMID:
28401244
20.

68Ga-PSMA PET/CT in Patients with Rising Prostatic-Specific Antigen After Definitive Treatment of Prostate Cancer: Detection Efficacy and Diagnostic accuracy.

Hamed MAG, Basha MAA, Ahmed H, Obaya AA, Afifi AHM, Abdelbary EH.

Acad Radiol. 2019 Apr;26(4):450-460. doi: 10.1016/j.acra.2018.05.020. Epub 2018 Jun 21.

PMID:
29935970

Supplemental Content

Support Center